GLP-1 (glucagon-like peptide-1) treatments for weight loss have been gaining a lot of attention recently, especially with medications like Wegovy® (semaglutide) and Mounjaro® (tirzepatide). These treatments are part of a class of drugs originally designed to treat type 2 diabetes, but they've shown remarkable effects in promoting weight loss as well. Dave Knapp reveals how GLP-1’s are changing lives in broader, profound ways. He delves into the history, science, and accessibility challenges of these treatments, offering insight into the emotional and social realities of living with obesity. Through personal stories from the “On The Pen” community, he showcases real-life triumphs and struggles, illustrating the transformative potential of GLP-1 medications beyond just weight loss. His work has been featured in Fortune, Bloomberg, Yahoo Finance, and Business Insider, solidifying his role as a trusted advocate and storyteller in the space.